Tickers

1. Composite Trajectory Verdict

The income statement carries the most weight for assessing DASH's trajectory because the business model's core question is whether scale translates into sustainable GAAP profitability after years of losses.

Composite Trajectory: Mixed

Annual results show clear improvement: FY 2025 revenue rose 28% to $13.7B (10-K 2025-12-31, Consolidated Statements of Operations), GAAP operating income turned positive at $723M vs a $38M loss in FY 2024, and net income reached $935M vs $123M (10-K 2025-12-31, Consolidated Statements of Operations). However, the most recent quarterly periods show deterioration beneath the top line: Q2 2026 operating income fell to $156M from $163M in Q2 2025 despite 36% revenue growth (10-Q 2026-06-30, Condensed Statements of Operations), and six-month operating income declined to $307M from $318M on 34% higher revenue (10-Q 2026-06-30, Condensed Statements of Operations). Cash generation improved sharply in Q2 2026, but the balance sheet added $2.7B of convertible debt and $3.2B of goodwill/intangibles from acquisitions, increasing leverage and impairment risk.

2. Red Flags

• Q2 2026 GAAP operating income declined 4% YoY ($163M → $156M) while revenue grew 36% ($3.28B → $4.45B) (10-Q 2026-06-30, Condensed Statements of Operations)
• Six-month GAAP operating income declined 3% YoY ($318M → $307M) on 34% revenue growth ($6.32B → $8.49B) (10-Q 2026-06-30, Condensed Statements of Operations)
• Q2 2026 GAAP net income fell 30% YoY ($285M → $200M) (10-Q 2026-06-30, Condensed Statements of Operations)
• Annual free cash flow growth nearly stalled: $1,802M → $1,826M (+1%) while revenue grew 28% (10-K 2025-12-31, MD&A Free Cash Flow reconciliation)
• Goodwill surged 138% to $5.5B and intangible assets 343% to $2.3B from Deliveroo, SevenRooms, Symbiosys acquisitions (10-K 2025-12-31, Consolidated Balance Sheets; Note 4)
• $2.75B of 0% Convertible Senior Notes due 2030 issued in May 2025, creating long-term cash settlement obligation (10-K 2025-12-31, Note 9)
• Accrued expenses and other current liabilities grew 39% YoY to $5.6B vs 28% revenue growth (10-K 2025-12-31, Consolidated Balance Sheets; Note 7)
• H1 2026 restructuring charges of $50M vs $1M in H1 2025 for country closure costs (10-Q 2026-06-30, MD&A Restructuring Charges)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

FY 2025 shows strong annual improvement: revenue +28% to $13.7B, gross margin expanded to 48.7% from 46.4%, operating income swung to +$723M from -$38M, and net income reached $935M from $123M (10-K 2025-12-31, Consolidated Statements of Operations). However, quarterly trends reversed in 2026: Q2 2026 operating margin compressed to 3.5% from 5.0% in Q2 2025 (operating income $156M on $4.45B revenue vs $163M on $3.28B revenue), and six-month operating margin fell to 3.6% from 5.0% ($307M on $8.49B vs $318M on $6.32B) (10-Q 2026-06-30, Condensed Statements of Operations). R&D expense grew 52% YoY in Q2 ($351M → $535M) and G&A 39% ($388M → $538M), outpacing revenue growth (10-Q 2026-06-30, MD&A). Depreciation and amortization doubled in Q2 ($159M → $295M) driven by acquired intangible amortization (10-Q 2026-06-30, MD&A Depreciation and Amortization).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Annual operating cash flow grew steadily: $1.67B → $2.13B → $2.43B (10-K 2025-12-31, Consolidated Statements of Cash Flows). Q2 2026 operating cash flow jumped to $944M from $504M in Q2 2025 (+87%), and free cash flow rose to $742M from $355M (+109%) (10-Q 2026-06-30, MD&A Free Cash Flow). Six-month operating cash flow reached $1.5B vs $1.1B in H1 2025 (derived from quarterly data in 10-Q 2026-06-30, Condensed Statements of Cash Flows). Investing cash flow turned heavily negative in FY 2025 (-$4.39B vs -$444M) due to $4.15B of acquisition payments (10-K 2025-12-31, Consolidated Statements of Cash Flows). Financing flipped to +$2.36B in FY 2025 from -$204M, driven by $2.72B convertible note proceeds and $341M warrant proceeds (10-K 2025-12-31, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew 53% to $19.7B at FY 2025 from $12.8B at FY 2024, primarily from acquisitions (10-K 2025-12-31, Consolidated Balance Sheets). Goodwill increased to $5.5B from $2.3B (+138%) and intangible assets to $2.3B from $510M (+343%) (10-K 2025-12-31, Consolidated Balance Sheets; Note 5). Cash and investments rose modestly to $6.3B from $6.2B (10-K 2025-12-31, MD&A Liquidity). Stockholders' equity grew 29% to $10.0B from $7.8B (10-K 2025-12-31, Consolidated Balance Sheets). However, convertible notes of $2.7B appeared on the balance sheet (zero in FY 2024), and current liabilities rose 39% to $6.1B from $4.4B, with accrued expenses up 39% to $5.6B (10-K 2025-12-31, Consolidated Balance Sheets; Note 7). The revolving credit facility remained undrawn with $800M capacity (10-K 2025-12-31, MD&A Credit Facility).

6. Data Gaps

• Standalone Q1 2026 GAAP income statement and cash flow figures (only six-month and Q2 2026 provided in 10-Q 2026-06-30)
• Q3 2026 and Q4 2026 quarterly results (not yet filed)
• Quarterly GAAP gross profit for Q2 2026 (MD&A provides only non-GAAP Contribution Profit of $1.6B)
• Quarterly breakdown of cost of revenue components (order management, platform, personnel) for 2026 periods
• Quarterly interest income detail for 2026 periods (annual only in 10-K)
• Quarterly provision for income taxes detail for 2026 periods (annual rate reconciliation only in 10-K)